Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Laboratory Corporation of America"


4 mentions found


The logo for Labcorp, Laboratory Corporation of America, a life sciences company is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., June 22, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 26 (Reuters) - Laboratory Corporation of America (LH.N) topped Wall Street expectations for quarterly adjusted profit on Thursday, as strength in its routine diagnostics business more than offset weak COVID test sales. Peer Danaher (DHR.N) also beat profit expectations earlier this week on the back of strong demand for its diagnostic tests for respiratory diseases. Labcorp reported adjusted profit of $3.38 per share, beating analysts' average estimate of $3.33 per share. The life sciences company also tightened its annual profit per share outlook to between $13.25 and $13.75, from $13 to $14 forecast earlier.
Persons: Brendan McDermid, Danaher, Labcorp, Mariam Sunny, Vinay Dwivedi Organizations: Laboratory Corporation of America, New York Stock Exchange, REUTERS, Quest Diagnostics, Thomson Locations: New York City, U.S, Bengaluru
Laboratory Corporation of America will pay the U.S. $2.1 million to settle allegations that it overbilled the Department of Defense for genetic tests that involved children and fetuses, the Justice Department announced Monday. Hecker-Gross' allegations surrounded genetic tests performed under a contract LabCorp entered with the Defense Department in 2012. Hecker-Gross alleged that LabCorp overcharged and double or triple-billed DOD for genetic tests performed by GeneDx. There were $210,959 in overcharges on 38 tests, including $113,525.50 for 21 tests billed between March 2016 and January 2017 alone, the lawsuit alleged. In 1996, LabCorp agreed to pay $187 million for fraudulently billing the government for unnecessary tests on elderly patients.
As investors worry about greater market volatility looming in 2023, Trivariate Research offers up some cheap, quality stocks that can be used to play defense. Yet investors struggle to find attractive stocks that are traditionally defensive, according to Trivariate Research. One way investors can find some attractive defensive names would be to look for cheap, quality stocks with low volatility. Pfizer is a defensive stock that is compellingly valued, according to the screen. Meanwhile, Check Point Software Technologies also looks like cheap quality, and was the only technology stock that met Trivariate's criteria, with a 0.63 beta.
Cramer's lighting round: I like Danaher over Philips
  + stars: | 2022-12-12 | by ( Krystal Hur | ) www.cnbc.com   time to read: 1 min
Loading chart...Novo Nordisk A/S : "Other than appreciation, I can not tell you a reason to ring the register." Loading chart...Koninklijke Philips NV : "That's just not a well-enough run company. We own Danaher for the Charitable Trust, and that's the best-run company in the industry." Loading chart...Icahn Enterprises LP : "I don't really know what they own, so it's kind of like a black box. Disclaimer: Cramer's Charitable Trust owns shares of Danaher.
Total: 4